James B. Breitmeyer - Feb 21, 2023 Form 4 Insider Report for Oncternal Therapeutics, Inc. (ONCT)

Role: Chief Executive Officer, Director
Signature: /s/Chase C. Leavitt, Attorney-in-fact
Stock symbol: ONCT
Transactions as of: Feb 21, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/24/2023, 03:00 PM
Previous filing: Jan 5, 2023
Next filing: Apr 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ONCT	Stock Option	Award	$0	+650K	$0.00	650K	Feb 21, 2023	Common Stock	650K	$0.96	Direct	F1
transaction	ONCT	Stock Option	Award	$0	+65K	$0.00	65K	Feb 21, 2023	Common Stock	65K	$0.96	By Spouse	F1
transaction	ONCT	Stock Option	Award	$0	+42.2K	$0.00	42.2K	Feb 21, 2023	Common Stock	42.2K	$0.81	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date.
F2	On November 14, 2018, the recipient received a stock option to purchase 168,787 shares, which vest on the achievement of certain pre-established strategic milestones. The issuer's Compensation Committee determined that two such strategic milestones were achieved, resulting in the vesting of 42,196 shares subject to the stock option effective February 21, 2023. 21,098 shares subject to the option remain unvested.

Content

25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date.

On November 14, 2018, the recipient received a stock option to purchase 168,787 shares, which vest on the achievement of certain pre-established strategic milestones. The issuer's Compensation Committee determined that two such strategic milestones were achieved, resulting in the vesting of 42,196 shares subject to the stock option effective February 21, 2023. 21,098 shares subject to the option remain unvested.